Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Chronic Heart Failure

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 405 articles:
HTML format



Single Articles


    March 2021
  1. LOOMBA RS, Villarreal EG, Flores S
    Letter by Loomba et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e755-e756.
    PubMed    


  2. NAVARRO CASTELLANOS I, Dahdah N
    Letter by Navarro Castellanos and Dahdah Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e759-e760.
    PubMed    


  3. CARDENAS SURI H, Jimomila Bening D
    Letter by Cardenas Suri and Jimomila Bening Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e757-e758.
    PubMed    


  4. REN C, Qian M, Han C
    Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
    Circulation. 2021;143:e761-e762.
    PubMed    


  5. YU H, Zhang F, Yan P, Zhang S, et al
    LARP7 Protects Against Heart Failure by Enhancing Mitochondrial Biogenesis.
    Circulation. 2021 Mar 5. doi: 10.1161/CIRCULATIONAHA.120.050812.
    PubMed     Abstract available


    February 2021
  6. UMAPATHI P, Banerjee PS, Zachara NE, Abrol N, et al
    Excessive O - GlcNAcylation Causes Heart Failure and Sudden Death.
    Circulation. 2021 Feb 17. doi: 10.1161/CIRCULATIONAHA.120.051911.
    PubMed     Abstract available


  7. PACKER DL, Piccini JP, Monahan KH, Al-Khalidi HR, et al
    Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.050991.
    PubMed     Abstract available


  8. NASSIF ME, Qintar M, Windsor SL, Jermyn R, et al
    Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial.
    Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.052503.
    PubMed     Abstract available


    January 2021

  9. Correction to: Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced.
    Circulation. 2021;143:e29.
    PubMed    



  10. Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Circulation. 2021;143:e30.
    PubMed    


  11. KOSIBOROD M
    Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Circulation. 2021;143:350-353.
    PubMed    


  12. CARNICELLI AP, Mentz RJ
    Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.
    Circulation. 2021;143:322-325.
    PubMed    


  13. HANG PZ, Zhao J
    Letter by Hang and Zhao Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
    Circulation. 2021;143:e24-e25.
    PubMed    


  14. VANDECASTEELE G, Mika D, Margaria JP, Ghigo A, et al
    Response by Vandecasteele et al to Letter Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
    Circulation. 2021;143:e26-e27.
    PubMed    


  15. BACKHAUS SJ, Lange T, George EF, Hellenkamp K, et al
    Exercise-Stress Real-time Cardiac Magnetic Resonance Imaging for Non-Invasive Characterisation of Heart Failure with Preserved Ejection Fraction: The HFpEF Stress Trial.
    Circulation. 2021 Jan 21. doi: 10.1161/CIRCULATIONAHA.120.051542.
    PubMed     Abstract available


  16. CHURCHILL TW, Li SX, Curreri L, Zern EK, et al
    Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort.
    Circulation. 2021;143:289-291.
    PubMed    


    December 2020
  17. MCMURRAY JJV, Packer M
    How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine.
    Circulation. 2020 Dec 30. doi: 10.1161/CIRCULATIONAHA.120.052926.
    PubMed    


  18. ZANNAD F, Cowie MR
    VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit.
    Circulation. 2020;142:2216-2218.
    PubMed    


    November 2020
  19. EZEKOWITZ JA, Savu A, Welsh RC, McAlister FA, et al
    Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?
    Circulation. 2020 Nov 30. doi: 10.1161/CIRCULATIONAHA.120.048015.
    PubMed    


  20. SARMA S, Howden E, Lawley J, Samels M, et al
    Central Command and the Regulation of Exercise Heart Rate Response in Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Nov 18. doi: 10.1161/CIRCULATIONAHA.120.048338.
    PubMed     Abstract available


  21. ALLEN LA, Venechuk G, McIlvennan CK, Page Ii RL, et al
    An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial.
    Circulation. 2020 Nov 17. doi: 10.1161/CIRCULATIONAHA.120.051863.
    PubMed     Abstract available



  22. Correction to: Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Circulation. 2020;142:e369.
    PubMed    


  23. LI X, Xue Q, Wang M, Zhou T, et al
    Adherence to a Healthy Sleep Pattern and Incident Heart Failure: A Prospective Study of 408802 UK Biobank Participants.
    Circulation. 2020 Nov 16. doi: 10.1161/CIRCULATIONAHA.120.050792.
    PubMed    


  24. LEE MMY, Brooksbank KJM, Wetherall K, Mangion K, et al
    Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.052186.
    PubMed     Abstract available


  25. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.
    Circulation. 2020 Nov 11. doi: 10.1161/CIRCULATIONAHA.120.051824.
    PubMed     Abstract available


  26. GIERULA J, Lowry JE, Paton MF, Cole CA, et al
    Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
    Circulation. 2020;142:e319-e320.
    PubMed    


  27. LAU CP, Tse HF
    Letter by Lau and Tse Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
    Circulation. 2020;142:e317-e318.
    PubMed    


  28. ALBERT CL, Carmona-Rubio AE, Weiss AJ, Procop GG, et al
    The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock With Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2.
    Circulation. 2020;142:1865-1870.
    PubMed    


  29. PATEL KV, Bahnson JL, Gaussoin SA, Johnson KC, et al
    Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.
    Circulation. 2020 Nov 9. doi: 10.1161/CIRCULATIONAHA.120.050941.
    PubMed    



  30. Correction to: Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020;142:e316.
    PubMed    


  31. HO JE, Redfield MM, Lewis GD, Paulus WJ, et al
    Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2020;142:1770-1780.
    PubMed     Abstract available


    October 2020
  32. HAHN VS, Knutsdottir H, Luo X, Bedi K, et al
    Myocardial Gene Expression Signatures in Human Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Oct 29. doi: 10.1161/CIRCULATIONAHA.120.050498.
    PubMed     Abstract available


  33. BIRKS EJ, Drakos SG, Patel SR, Lowes BD, et al
    A Prospective Multicentre Study of Myocardial Recovery Using Left Ventricular Assist Devices (REmission from Stage D Heart Failure: RESTAGE-HF): Medium Term and Primary Endpoint Results.
    Circulation. 2020 Oct 26. doi: 10.1161/CIRCULATIONAHA.120.046415.
    PubMed     Abstract available


  34. ZANNAD F, Ferreira JP, Pocock SJ, Zeller C, et al
    Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial.
    Circulation. 2020 Oct 23. doi: 10.1161/CIRCULATIONAHA.120.051685.
    PubMed     Abstract available


  35. PACKER M, Anker SD, Butler J, Filippatos GS, et al
    Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Circulation. 2020 Oct 21. doi: 10.1161/CIRCULATIONAHA.120.051783.
    PubMed     Abstract available


  36. THIBODEAU JT, Gorodeski EZ
    Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure.
    Circulation. 2020;142:1507-1509.
    PubMed    



  37. Correction to: Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
    Circulation. 2020;142:e234.
    PubMed    



  38. Correction to: Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
    Circulation. 2020;142:e236.
    PubMed    


  39. JHUND PS, Solomon SD, Docherty KF, Heerspink HJL, et al
    Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF.
    Circulation. 2020 Oct 12. doi: 10.1161/CIRCULATIONAHA.120.050391.
    PubMed     Abstract available


  40. SANDERS-VAN WIJK S, Tromp J, Beussink-Nelson L, Hage C, et al
    Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study.
    Circulation. 2020 Oct 9. doi: 10.1161/CIRCULATIONAHA.120.045810.
    PubMed     Abstract available


  41. COSENTINO F, Cannon CP, Cherney DZI, Masiukiewicz U, et al
    Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Circulation. 2020 Oct 7. doi: 10.1161/CIRCULATIONAHA.120.050255.
    PubMed     Abstract available


    September 2020
  42. TOBE SW, Poon S
    Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes.
    Circulation. 2020;142:1246-1248.
    PubMed    


  43. KHAN MS, Fonarow GC, McGuire DK, Hernandez AF, et al
    Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Circulation. 2020;142:1205-1218.
    PubMed     Abstract available


  44. LI J, Tan Y, Passariello CL, Martinez EC, et al
    Signalosome-Regulated SRF Phosphorylation Determining Myocyte Growth in Width versus Length as a Therapeutic Target for Heart Failure.
    Circulation. 2020 Sep 16. doi: 10.1161/CIRCULATIONAHA.119.044805.
    PubMed     Abstract available


  45. GRODIN JL, Tang WHW
    Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney.
    Circulation. 2020;142:1055-1058.
    PubMed    


  46. PARCHA V, Patel N, Kalra R, Arora G, et al
    Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial.
    Circulation. 2020;142:1018-1020.
    PubMed    


  47. VERBRUGGE FH, Guazzi M, Testani JM, Borlaug BA, et al
    Altered Hemodynamics and End-Organ Damage in Heart Failure: Impact on the Lung and Kidney.
    Circulation. 2020;142:998-1012.
    PubMed     Abstract available


  48. CHAN MY, Efthymios M, Tan SH, Pickering JW, et al
    Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
    Circulation. 2020 Sep 4. doi: 10.1161/CIRCULATIONAHA.119.045158.
    PubMed     Abstract available


  49. DOCHERTY KF, Jhund PS, Anand I, Bengtsson O, et al
    Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
    Circulation. 2020 Sep 4. doi: 10.1161/CIRCULATIONAHA.120.047480.
    PubMed     Abstract available


  50. DURSTENFELD MS, Hsue PY
    An Unusual, Reversible Cause of Acute High-Output Heart Failure Complicated by Refractory Shock.
    Circulation. 2020;142:901-905.
    PubMed    


    August 2020
  51. MORDI NA, Mordi IR, Singh JS, McCrimmon RJ, et al
    Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.048739.
    PubMed     Abstract available


  52. LOPES RD, Alexander KP, Stevens SR, Reynolds HR, et al
    Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.050304.
    PubMed     Abstract available


  53. MC CAUSLAND FR, Lefkowitz MP, Claggett B, Anavekar NS, et al
    Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction.
    Circulation. 2020 Aug 17. doi: 10.1161/CIRCULATIONAHA.120.047643.
    PubMed     Abstract available


  54. CHEN F, Chen ZQ, Zhu JJ
    Letter by Chen et al Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
    Circulation. 2020;142:e67-e68.
    PubMed    


  55. LEWIS AA, de Lemos JA
    Response by Lewis and de Lemos to Letter Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
    Circulation. 2020;142:e69-e70.
    PubMed    


  56. SIMPSON JM, Newburger JW
    Multisystem Inflammatory Syndrome in Children in Association With COVID-19.
    Circulation. 2020;142:437-440.
    PubMed    


    July 2020
  57. JACKSON AM, Dewan P, Anand IS, Belohlavek J, et al
    Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Circulation. 2020 Jul 16. doi: 10.1161/CIRCULATIONAHA.120.047077.
    PubMed     Abstract available


  58. JACKSON AM, Jhund PS, Solomon SD, McMurray JJV, et al
    Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Circulation. 2020;142:e5-e6.
    PubMed    


  59. WU K, Zhao S
    Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Circulation. 2020;142:e3-e4.
    PubMed    


    June 2020
  60. AL-KHATIB SM, Benjamin EJ, Albert CM, Alonso A, et al
    Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop.
    Circulation. 2020;141:1915-1926.
    PubMed     Abstract available


  61. PANDEY A, Vaduganathan M, Arora S, Qamar A, et al
    Temporal Trends in Prevalence & Prognostic Implications of Comorbidities Among Patients with Acute Decompensated Heart Failure: The ARIC Study Community Surveillance.
    Circulation. 2020 Jun 3. doi: 10.1161/CIRCULATIONAHA.120.047019.
    PubMed     Abstract available


  62. HONG YS, Longchamps RJ, Zhao D, Castellani CA, et al
    Mitochondrial DNA Copy Number and Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study.
    Circulation. 2020;141:1823-1825.
    PubMed    


  63. SELVARAJ S, Kelly DP, Margulies KB
    Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.
    Circulation. 2020;141:1800-1812.
    PubMed     Abstract available


    May 2020
  64. SARMA S, Levine BD
    Response by Sarma and Levine to Letter Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
    Circulation. 2020;141:e822.
    PubMed    


  65. KOMAMURA K
    Letter by Komamura Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
    Circulation. 2020;141:e819.
    PubMed    


  66. BELKIN M, Michou E, Mueller C
    Letter by Belkin et al Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
    Circulation. 2020;141:e820-e821.
    PubMed    


  67. NWABUO CC, Rana JS
    Letter by Nwabuo and Rana Regarding Article, "Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction".
    Circulation. 2020;141:e817-e818.
    PubMed    


  68. BELHADJER Z, Meot M, Bajolle F, Khraiche D, et al
    Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic.
    Circulation. 2020 May 17. doi: 10.1161/CIRCULATIONAHA.120.048360.
    PubMed     Abstract available


  69. GRIFFIN M, Rao VS, Ivey-Miranda J, Fleming J, et al
    Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects.
    Circulation. 2020 May 15. doi: 10.1161/CIRCULATIONAHA.120.045691.
    PubMed     Abstract available



  70. Correction to: Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction: Implications for Systolic and Diastolic Reserve Limitations.
    Circulation. 2020;141:e809.
    PubMed    


    April 2020
  71. BADOLIA R, Ramadurai DKA, Abel ED, Ferrin P, et al
    The Role of Non-Glycolytic Glucose Metabolism in Myocardial Recovery upon Mechanical Unloading and Circulatory Support in Chronic Heart Failure.
    Circulation. 2020 Apr 30. doi: 10.1161/CIRCULATIONAHA.119.044452.
    PubMed     Abstract available


  72. KITKO L, McIlvennan CK, Bidwell JT, Dionne-Odom JN, et al
    Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2020 Apr 30:CIR0000000000000768. doi: 10.1161/CIR.0000000000000768.
    PubMed     Abstract available


  73. WHITE-WILLIAMS C, Rossi LP, Bittner VA, Driscoll A, et al
    Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2020 Apr 30:CIR0000000000000767. doi: 10.1161/CIR.0000000000000767.
    PubMed     Abstract available


  74. ARMSTRONG PW
    Enhancing Cardiovascular Care: Global Collaboration Is How It Happens.
    Circulation. 2020;141:1357-1359.
    PubMed    


  75. GIERULA J, Lowry JE, Paton MF, Cole CA, et al
    Personalised Rate-Response Programming Improves Exercise Tolerance After Six Months in People with Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study.
    Circulation. 2020 Apr 17. doi: 10.1161/CIRCULATIONAHA.119.045066.
    PubMed     Abstract available


  76. KARAM S, Margaria JP, Bourcier A, Mika D, et al
    Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
    Circulation. 2020 Apr 8. doi: 10.1161/CIRCULATIONAHA.119.042573.
    PubMed     Abstract available


  77. FRIED JA, Ramasubbu K, Bhatt R, Topkara VK, et al
    The Variety of Cardiovascular Presentations of COVID-19.
    Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164.
    PubMed    


  78. CHIRINOS JA, Zhao L, Jia Y, Frej C, et al
    Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.
    Circulation. 2020 Apr 2. doi: 10.1161/CIRCULATIONAHA.119.045323.
    PubMed     Abstract available


    March 2020
  79. TOTO RD
    Leveraging the Peritoneum as a New Diuretic Strategy for Heart Failure.
    Circulation. 2020;141:1054-1056.
    PubMed    


  80. SHAH SJ, Borlaug BA, Kitzman DW, McCulloch AD, et al
    Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.
    Circulation. 2020;141:1001-1026.
    PubMed     Abstract available


  81. LITTMANN L
    Letter by Littmann Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure R
    Circulation. 2020;141:e646-e647.
    PubMed    


  82. SCHRAGE B, Linde C, Braunschweig F, Savarese G, et al
    Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedis
    Circulation. 2020;141:e648-e649.
    PubMed    


  83. CHARTON M, Flecher E, Leclercq C, Delmas C, et al
    Suicide Attempts Among LVAD Recipients: Real-Life Data From the ASSIST-ICD Study.
    Circulation. 2020;141:934-936.
    PubMed    


  84. CAPORIZZO MA, Chen CY, Bedi K, Margulies KB, et al
    Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium.
    Circulation. 2020;141:902-915.
    PubMed     Abstract available


  85. PANDEY A, Patel KV, Bahnson JL, Gaussoin SA, et al
    Association of Intensive Lifestyle Intervention, Fitness and Body Mass Index with Risk of Heart Failure in Overweight or Obese Adults with Type 2 Diabetes Mellitus: An Analysis from the Look AHEAD Trial.
    Circulation. 2020 Mar 5. doi: 10.1161/CIRCULATIONAHA.119.044865.
    PubMed     Abstract available


  86. SCHIATTARELLA GG, Tong D, Hill JA
    Can HFpEF and HFrEF Coexist?
    Circulation. 2020;141:709-711.
    PubMed    


    February 2020
  87. KUEHN BM
    Race May Influence Transplant Decision Making in Heart Failure: Studies Also Detail Disparities in Hypertension Diagnosis, Statin Prescribing.
    Circulation. 2020;141:694-695.
    PubMed    


  88. ROSENKRANZ S, Howard LS, Gomberg-Maitland M, Hoeper MM, et al
    Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure.
    Circulation. 2020;141:678-693.
    PubMed     Abstract available


  89. OMIYA S, Omori Y, Taneike M, Murakawa T, et al
    Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts.
    Circulation. 2020;141:667-677.
    PubMed     Abstract available


  90. HILFIKER-KLEINER D, Konig T, Bauersachs J
    Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure.
    Circulation. 2020;141:589-591.
    PubMed    


  91. KHOSROW-KHAVAR F, Filion KB, Bouganim N, Suissa S, et al
    Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Circulation. 2020;141:549-559.
    PubMed     Abstract available


  92. KUEHN BM
    Biomarkers May Help Stratify Patient Heart Failure Risk, Guide Treatment.
    Circulation. 2020;141:399-400.
    PubMed    


  93. BOZKURT B, Ezekowitz J
    Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials.
    Circulation. 2020;141:362-366.
    PubMed    


    January 2020
  94. BERGMARK BA, Bhatt DL, McGuire DK, Scirica BM, et al
    Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
    Circulation. 2020;141:e57-e58.
    PubMed    


  95. MORDI IR, Mohan M, Lang CC
    Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
    Circulation. 2020;141:e55-e56.
    PubMed    


  96. GOMES CPDC, Schroen B, Kuster GM, Robinson EL, et al
    Regulatory RNAs in Heart Failure.
    Circulation. 2020;141:313-328.
    PubMed     Abstract available


  97. LEWIS AA, Ayers CR, Selvin E, Neeland I, et al
    Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multi-Cohort Study.
    Circulation. 2020 Jan 14. doi: 10.1161/CIRCULATIONAHA.119.043628.
    PubMed     Abstract available


  98. HIEDA M, Sarma S, Hearon CM Jr, Dias KA, et al
    Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction.
    Circulation. 2020;141:115-123.
    PubMed     Abstract available


  99. PATERSON DI, Wells G, Erthal F, Mielniczuk L, et al
    OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients with Non-Ischemic Heart Failure (IMAGE-HF 1B).
    Circulation. 2020 Jan 8. doi: 10.1161/CIRCULATIONAHA.119.043964.
    PubMed     Abstract available


  100. PACKER M, Lam CSP, Lund LH, Redfield MM, et al
    Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy.
    Circulation. 2020;141:4-6.
    PubMed    


  101. FAYSSOIL A
    Letter by Fayssoil Regarding Article, "Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction".
    Circulation. 2020;141:e1-e2.
    PubMed    


    December 2019
  102. BUTLER J, Packer M, Greene SJ, Fiuzat M, et al
    Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
    Circulation. 2019;140:2108-2118.
    PubMed     Abstract available


    November 2019
  103. TONG D, Schiattarella GG, Jiang N, May HI, et al
    Female Sex Is Protective in a Preclinical Model of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2019;140:1769-1771.
    PubMed    


  104. SOLOMON SD, Vaduganathan M, Claggett BL, Packer M, et al
    Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044586.
    PubMed     Abstract available


  105. MCMURRAY JJV, Jackson AM, Lam CSP, Redfield MM, et al
    Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF.
    Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044491.
    PubMed     Abstract available


  106. KOSIBOROD MN, Jhund P, Docherty KF, Diez M, et al
    Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial.
    Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044138.
    PubMed     Abstract available


  107. FELKER GM
    Building the Foundation for a New Era of Quadruple Therapy in Heart Failure.
    Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044578.
    PubMed     Abstract available


  108. MARTINEZ FA, Serenelli M, Nicolau JC, Petrie MC, et al
    Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
    Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044133.
    PubMed    


  109. DEHARO P, Bisson A, Herbert J, Lacour T, et al
    Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients with Aortic Stenosis: Data from a Nationwide Analysis.
    Circulation. 2019 Nov 16. doi: 10.1161/CIRCULATIONAHA.119.043971.
    PubMed     Abstract available


  110. ARNOTT C, Neal B
    Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
    Circulation. 2019;140:1623-1625.
    PubMed    


  111. JIA X, Sun W, Hoogeveen RC, Nambi V, et al
    Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study".
    Circulation. 2019;140:e772-e773.
    PubMed    


  112. LI D, Cheng Y
    Letter by Li and Cheng Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study".
    Circulation. 2019;140:e770-e771.
    PubMed    


  113. DJOUSSE L, Cook NR, Kim E, Bodar V, et al
    Supplementation with Vitamin D and/or Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044645.
    PubMed     Abstract available


    October 2019
  114. MARTINI E, Kunderfranco P, Peano C, Carullo P, et al
    Single Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation.
    Circulation. 2019 Oct 30. doi: 10.1161/CIRCULATIONAHA.119.041694.
    PubMed     Abstract available


  115. ELGHAZALY H, Hajiev S, Singh P
    Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
    Circulation. 2019;140:e738-e739.
    PubMed    


  116. KATO ET, Sabatine MS, Wiviott SD
    Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
    Circulation. 2019;140:e740-e741.
    PubMed    


  117. DRAZNER MH, Stevenson LW
    Relief and Prevention of Congestion in Heart Failure Enhance Quality and Length of Life.
    Circulation. 2019;140:1380-1382.
    PubMed    


  118. TROMP J, Hage C, Ouwerkerk W, Sanders-van Wijk S, et al
    Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2019;140:1359-1361.
    PubMed    


  119. KUEHN BM
    Gut Microbes Role in Heart Failure Explored.
    Circulation. 2019;140:1217-1218.
    PubMed    


  120. TIAN R, Colucci WS, Arany Z, Bachschmid MM, et al
    Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure-A Report from the 2018 National Heart, Lung, and Blood Institute Workshop
    Circulation. 2019;140:1205-1216.
    PubMed     Abstract available


    September 2019
  121. BARON SJ, Wang K, Arnold SV, Magnuson EA, et al
    Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial.
    Circulation. 2019 Sep 29. doi: 10.1161/CIRCULATIONAHA.119.043275.
    PubMed     Abstract available


  122. BONOW RO, Mark DB, O'Gara PT
    Coapting Cost and Clinical Outcomes in Transcatheter Intervention for Secondary Mitral Regurgitation.
    Circulation. 2019 Sep 29. doi: 10.1161/CIRCULATIONAHA.119.043408.
    PubMed    


  123. AUNG N, Vargas JD, Yang C, Cabrera CP, et al
    Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated with Cardiac Morphogenesis and Heart Failure Development.
    Circulation. 2019 Sep 25. doi: 10.1161/CIRCULATIONAHA.119.041161.
    PubMed     Abstract available


  124. FUDIM M, White J, Pagidipati NJ, Lokhnygina Y, et al
    Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Circulation. 2019 Sep 23. doi: 10.1161/CIRCULATIONAHA.119.041659.
    PubMed     Abstract available


  125. KHAZANIE P, Drazner MH
    The Blurred Line between Gaming and Patient Advocacy: Heart Transplant Listing Decisions in the Modern Era.
    Circulation. 2019 Sep 18. doi: 10.1161/CIRCULATIONAHA.119.043034.
    PubMed    



  126. Correction to: Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.
    Circulation. 2019;140:e692.
    PubMed    


  127. NASSIF ME, Windsor S, Tang F, Khariton Y, et al
    Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Circulation. 2019 Sep 16. doi: 10.1161/CIRCULATIONAHA.119.042929.
    PubMed    


  128. SELVARAJ S, Claggett B, Pozzi A, McMurray JJV, et al
    Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients with Heart Failure and Reduced Ejection Fraction:PARADIGM-HF.
    Circulation. 2019 Sep 12. doi: 10.1161/CIRCULATIONAHA.119.039920.
    PubMed     Abstract available


  129. SCHRAGE B, Uijl A, Benson L, Westermann D, et al
    Association Between Use of Primary Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients with Heart Failure: A Prospective Propensity-Score Matched Analysis from the Swedish Heart Failure Registry.
    Circulation. 2019 Sep 3. doi: 10.1161/CIRCULATIONAHA.119.043012.
    PubMed     Abstract available


  130. AL-KHATIB SM, Kusumoto FM
    Implantable Cardioverter Defibrillators Have Stood the Test of Time!
    Circulation. 2019 Sep 3. doi: 10.1161/CIRCULATIONAHA.119.043354.
    PubMed    


    August 2019
  131. BERG DD, Wiviott SD, Scirica BM, Gurmu Y, et al
    Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019 Aug 31. doi: 10.1161/CIRCULATIONAHA.119.042685.
    PubMed    


  132. GRACIA E, Hamid A, Butler J
    Timely Management of New-Onset Heart Failure.
    Circulation. 2019;140:621-623.
    PubMed    


  133. CLELAND JGF, Pellicori P
    Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure.
    Circulation. 2019;140:538-541.
    PubMed    


  134. PACKER M
    Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Circulation. 2019;140:443-445.
    PubMed    


    July 2019
  135. BERGMARK BA, Bhatt DL, McGuire DK, Cahn A, et al
    Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
    Circulation. 2019 Jul 31. doi: 10.1161/CIRCULATIONAHA.119.040144.
    PubMed     Abstract available


  136. SENNI M, Caravita S, Paulus WJ
    Do Existing Definitions Identify Subgroup Phenotypes or Reflect the Natural History of Heart Failure With Preserved Ejection Fraction?
    Circulation. 2019;140:366-369.
    PubMed    


  137. FAN Q, Mao H, Angelini A, Coarfa C, et al
    Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction.
    Circulation. 2019;140:440-442.
    PubMed    


  138. FELDMAN AM, Gerhard GS, Cheung JY
    Letter by Feldman et al Regarding Article, "Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery".
    Circulation. 2019;140:e5-e6.
    PubMed    


  139. ARAGAM KG, Chaffin M, Ellinor PT, Kathiresan S, et al
    Response by Aragam et al to Letter Regarding Article, "Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery".
    Circulation. 2019;140:e7-e8.
    PubMed    


    June 2019
  140. VERMA S, Lam CSP, Kosiborod M
    Empagliflozin and Heart Failure.
    Circulation. 2019;139:2831-2834.
    PubMed    


  141. KRONLAGE M, Dewenter M, Grosso J, Fleming T, et al
    O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart from Failure.
    Circulation. 2019 Jun 14. doi: 10.1161/CIRCULATIONAHA.117.031942.
    PubMed     Abstract available


  142. GOLDENBERG JR, Carley AN, Ji R, Zhang X, et al
    Preservation of Acyl Coenzyme A Attenuates Pathological and Metabolic Cardiac Remodeling Through Selective Lipid Trafficking.
    Circulation. 2019;139:2765-2777.
    PubMed     Abstract available


  143. DUNLAY SM, Givertz MM, Aguilar D, Allen LA, et al
    Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.
    Circulation. 2019 Jun 6:CIR0000000000000691. doi: 10.1161/CIR.0000000000000691.
    PubMed     Abstract available


  144. BRANCH KR, Probstfield JL, Eikelboom JW, Bosch J, et al
    Rivaroxaban With or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial.
    Circulation. 2019 Jun 5. doi: 10.1161/CIRCULATIONAHA.119.039609.
    PubMed     Abstract available


    May 2019
  145. BENFARI G, Antoine C, Miller WL, Thapa P, et al
    Excess Mortality Associated with Functional Tricuspid Regurgitation Complicating Heart Failure with Reduced Ejection Fraction.
    Circulation. 2019 May 23. doi: 10.1161/CIRCULATIONAHA.118.038946.
    PubMed     Abstract available


  146. VAN DER MEER P, van der Wal HH, Melenovsky V
    Mitochondrial Function, Skeletal Muscle Metabolism, and Iron Deficiency in Heart Failure.
    Circulation. 2019;139:2399-2402.
    PubMed    


  147. TESTANI JM, Inzucchi SE, Voors AA
    Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
    Circulation. 2019;139:2383-2385.
    PubMed    


  148. SEPEHRVAND N, Alemayehu W, Dyck GJB, Dyck JRB, et al
    External Validation of the H2F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction.
    Circulation. 2019;139:2377-2379.
    PubMed    


  149. NYSTROM T, Sartipy U, Contardi A, Lind M, et al
    Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction.
    Circulation. 2019;139:2380-2382.
    PubMed    


  150. SMITH GL, Eisner DA
    Calcium Buffering in the Heart in Health and Disease.
    Circulation. 2019;139:2358-2371.
    PubMed     Abstract available


  151. ENRIQUEZ-SARANO M, Michelena HI, Grigioni F
    Treatment of Functional Mitral Regurgitation.
    Circulation. 2019;139:2289-2291.
    PubMed    


  152. GOPINATHANNAIR R, Cornwell WK, Dukes JW, Ellis CR, et al
    Device Therapy and Arrhythmia Management in Left Ventricular Assist Device Recipients: A Scientific Statement From the American Heart Association.
    Circulation. 2019;139:e967-e989.
    PubMed     Abstract available


  153. PACKER M, Grayburn PA
    Contrasting Effects of Pharmacological, Procedural and Surgical Interventions on Proportionate and Disproportionate Functional Mitral Regurgitation in Chronic Heart Failure.
    Circulation. 2019 May 1. doi: 10.1161/CIRCULATIONAHA.119.039612.
    PubMed     Abstract available


    April 2019
  154. JIA X, Sun W, Hoogeveen RC, Nambi V, et al
    High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
    Circulation. 2019 Apr 29. doi: 10.1161/CIRCULATIONAHA.118.038772.
    PubMed     Abstract available


  155. SANO M, Goto S
    Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
    Circulation. 2019;139:1985-1987.
    PubMed    


  156. RANGASWAMI J, Bhalla V, Blair JEA, Chang TI, et al
    Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.
    Circulation. 2019;139:e840-e878.
    PubMed     Abstract available


  157. SEGAR MW, Patel KV, Berry JD, Grodin JL, et al
    Generalizability and Implications of the H2FPEF Score in a Cohort of Patients With Heart Failure With Preserved Ejection Fraction.
    Circulation. 2019;139:1851-1853.
    PubMed    


  158. MORROW DA, Velazquez EJ, DeVore AD, Desai AS, et al
    Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
    Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039331.
    PubMed    


  159. PATORNO E, Pawar A, Franklin JM, Najafzadeh M, et al
    Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study.
    Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.039177.
    PubMed     Abstract available


    March 2019
  160. NIELSEN R, Moller N, Gormsen LC, Tolbod LP, et al
    Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
    Circulation. 2019 Mar 19. doi: 10.1161/CIRCULATIONAHA.118.036459.
    PubMed     Abstract available


  161. BOTS SH, den Ruijter HM
    Recommended Heart Failure Medications and Adverse Drug Reactions in Women.
    Circulation. 2019;139:1469-1471.
    PubMed    


  162. KATO ET, Silverman MG, Mosenzon O, Zelniker TA, et al
    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.040130.
    PubMed     Abstract available


  163. VERMA S, McMurray JJV
    The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights from DECLARE-TIMI 58.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.040514.
    PubMed     Abstract available


  164. FURTADO RHM, Bonaca MP, Raz I, Zelniker TA, et al
    Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039996.
    PubMed     Abstract available


  165. JUKEMA JW, Timal RJ, Rotmans JI, Hensen LCR, et al
    Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients: The Prospective Randomized Controlled ICD2 Trial.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039818.
    PubMed     Abstract available


  166. FIGTREE GA, Radholm K, Barrett TD, Perkovic V, et al
    Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.
    Circulation. 2019 Mar 17. doi: 10.1161/CIRCULATIONAHA.119.040057.
    PubMed     Abstract available


  167. KUMAR AA, Kelly DP, Chirinos JA
    Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2019;139:1435-1450.
    PubMed     Abstract available


  168. SAVARESE G, Sattar N, Januzzi J, Verma S, et al
    Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
    Circulation. 2019;139:1458-1460.
    PubMed    


    February 2019
  169. SAHA P, Potiny P, Rigdon J, Morello M, et al
    Substantial Cardiovascular Morbidity in Adults with Lower-Complexity Congenital Heart Disease.
    Circulation. 2019 Feb 28. doi: 10.1161/CIRCULATIONAHA.118.037064.
    PubMed     Abstract available


  170. COLLINS SP, Pang PS
    ACUTE Heart Failure Risk Stratification.
    Circulation. 2019;139:1157-1161.
    PubMed    


  171. RAWSHANI A, Rawshani A, Sattar N, Franzen S, et al
    Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes.
    Circulation. 2019 Feb 25. doi: 10.1161/CIRCULATIONAHA.118.037454.
    PubMed     Abstract available


  172. HSICH EM
    Sex Differences in Advanced Heart Failure Therapies.
    Circulation. 2019;139:1080-1093.
    PubMed     Abstract available


  173. CHARLES-EDWARDS G, Amaral N, Sleigh A, Ayis S, et al
    Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients with Chronic Heart Failure and Iron Deficiency: The FERRIC-HF II Randomized Mechanistic Trial.
    Circulation. 2019 Feb 19. doi: 10.1161/CIRCULATIONAHA.118.038516.
    PubMed     Abstract available


  174. DEL BUONO MG, Carbone S, Abbate A
    Letter by Del Buono et al Regarding Article, "A Simple, Evidence-Based Approach To Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2019;139:990-991.
    PubMed    


  175. COBOS GIL MA
    Letter by Cobos Gil Regarding Article, "A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2019;139:989.
    PubMed    


  176. REDDY YNV, Borlaug BA
    Response by Reddy and Borlaug to Letters Regarding Article, "A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2019;139:992-993.
    PubMed    


  177. MORDI IR, Pearson ER, Palmer CNA, Doney ASF, et al
    Differential Association of Genetic Risk of Coronary Artery Disease With Development of Heart Failure With Reduced Versus Preserved Ejection Fraction.
    Circulation. 2019;139:986-988.
    PubMed    


  178. LEE DP, Tan WLW, Anene-Nzelu CG, Lee CJM, et al
    A Robust CTCF-Based Chromatin Architecture Underpins Epigenetic Changes in the Heart Failure Stress-Gene Response.
    Circulation. 2019 Feb 5. doi: 10.1161/CIRCULATIONAHA.118.036726.
    PubMed     Abstract available


    January 2019
  179. CHEN Y, Nilsson J, Liang C
    Letter by Chen et al Regarding Article, "Heart Failure Stimulates Tumor Growth by Circulating Factors".
    Circulation. 2019;139:716-717.
    PubMed    


  180. MEIJERS WC, de Boer RA
    Response by Meijers and de Boer to Letters Regarding Article, "Heart Failure Stimulates Tumor Growth by Circulating Factors".
    Circulation. 2019;139:720-721.
    PubMed    


  181. DEVORE AD, Bhatt AS
    Influenza Vaccination in Patients With Heart Failure.
    Circulation. 2019;139:587-589.
    PubMed    


  182. ZHANG J, Lan HY, Wan S
    Letter by Zhang et al Regarding Article, "Heart Failure Stimulates Tumor Growth by Circulating Factors".
    Circulation. 2019;139:718-719.
    PubMed    


  183. MATHIYALAGAN P, Adamiak M, Mayourian J, Sassi Y, et al
    FTO-Dependent N(6)-Methyladenosine Regulates Cardiac Function During Remodeling and Repair.
    Circulation. 2019;139:518-532.
    PubMed     Abstract available


  184. FIGTREE GA, Radholm K, Neal B
    Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:418-419.
    PubMed    


  185. KOH KK
    Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:416-417.
    PubMed    


  186. ZANNAD F, Rossignol P
    Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.
    Circulation. 2019;139:362-365.
    PubMed    


  187. ZHOU L, Li Z, Wang DW
    Response by Zhou et al to Letter Regarding Article, "Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure".
    Circulation. 2019;139:301-302.
    PubMed    


  188. GREENE SJ, Butler J
    Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019;139:152-154.
    PubMed    


  189. FRANGOGIANNIS NG
    Protean Functions and Phenotypic Plasticity of Regulatory T Cells in Chronic Ischemic Heart Failure.
    Circulation. 2019;139:222-225.
    PubMed    


  190. MORIS D, Karachaliou GS, Karaolanis G
    Letter by Moris et al Regarding Article, "Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure".
    Circulation. 2019;139:299-300.
    PubMed    


  191. ANDERSEN S, Nielsen-Kudsk JE, Vonk Noordegraaf A, de Man FS, et al
    Right Ventricular Fibrosis.
    Circulation. 2019;139:269-285.
    PubMed     Abstract available


    December 2018
  192. ANAND I, Gupta P
    Response by Anand and Gupta to Letter Regarding Article, "Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies".
    Circulation. 2018;138:2976-2977.
    PubMed    


  193. DE LAS NIEVES LOPEZ MA
    Letter by de las Nieves Lopez Regarding Article, "Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies".
    Circulation. 2018;138:2974-2975.
    PubMed    


  194. TROMP J, MacDonald MR, Tay WT, Teng TK, et al
    Heart Failure With Preserved Ejection Fraction in the Young.
    Circulation. 2018;138:2763-2773.
    PubMed     Abstract available


  195. AMBROSY AP, Parzynski CS, Friedman DJ, Fudim M, et al
    Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?
    Circulation. 2018;138:2787-2797.
    PubMed     Abstract available


  196. JERNBERG T, Lindahl B, Alfredsson J, Berglund E, et al
    Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction
    Circulation. 2018;138:2754-2762.
    PubMed     Abstract available


  197. MODIN D, Jorgensen ME, Gislason G, Jensen JS, et al
    Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study.
    Circulation. 2018 Dec 10. doi: 10.1161/CIRCULATIONAHA.118.036788.
    PubMed     Abstract available


  198. FITCHETT D, Inzucchi SE, Cannon CP, McGuire DK, et al
    Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
    Circulation. 2018 Dec 6. doi: 10.1161/CIRCULATIONAHA.118.037778.
    PubMed     Abstract available


  199. KANG DH, Park SJ, Shin SH, Hong GR, et al
    Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study.
    Circulation. 2018 Dec 5. doi: 10.1161/CIRCULATIONAHA.118.037077.
    PubMed     Abstract available


  200. DIDIER R, Eltchaninoff H, Donzeau-Gouge P, Chevreul K, et al
    Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients.
    Circulation. 2018;138:2597-2607.
    PubMed     Abstract available


    November 2018
  201. LEE DS, Lee JS, Schull MJ, Borgundvaag B, et al
    Prospective Validation of the Emergency Heart Failure Mortality Risk Grad for Acute Heart Failure: The Acute Congestive Heart Failure Urgent Care Evaluation (ACUTE) Study.
    Circulation. 2018 Nov 29. doi: 10.1161/CIRCULATIONAHA.118.035509.
    PubMed     Abstract available


  202. SHAH R, Latham SB
    Letter by Shah and Latham Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With the Guidelines-Heart Failure".
    Circulation. 2018;138:2303-2304.
    PubMed    


  203. REISMAN L
    Letter by Reisman Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure".
    Circulation. 2018;138:2301-2302.
    PubMed    


  204. MAHLA RS
    Letter by Mahla Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure".
    Circulation. 2018;138:2305.
    PubMed    


  205. KUMBHANI DJ, Fonarow GC, Heidenreich PA, Schulte PJ, et al
    Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure".
    Circulation. 2018;138:2306-2307.
    PubMed    


  206. THYGESEN K, Alpert JS, Jaffe AS, Chaitman BR, et al
    Fourth Universal Definition of Myocardial Infarction (2018).
    Circulation. 2018;138:e618-e651.
    PubMed    


  207. EVERETT BM, Cornel J, Lainscak M, Anker SD, et al
    Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038010.
    PubMed     Abstract available


  208. MCGUIRE DK, Alexander JH, Johansen OE, Perkovic V, et al
    Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038352.
    PubMed     Abstract available


  209. ARAGAM KG, Chaffin M, Levinson RT, McDermott G, et al
    Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery.
    Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.035774.
    PubMed     Abstract available


    October 2018
  210. MATSUMOTO J, Takada S, Kinugawa S, Furihata T, et al
    Brain-Derived Neurotrophic Factor Improves Limited Exercise Capacity in Mice With Heart Failure.
    Circulation. 2018;138:2064-2066.
    PubMed    


  211. LEROY J, Fischmeister R
    Inhibit a Phosphodiesterase to Treat Heart Failure?
    Circulation. 2018;138:2003-2006.
    PubMed    


  212. KOK W, Stienen S
    Response by Kok and Stienen to Letter Regarding Article, "NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Adm
    Circulation. 2018;138:1910-1911.
    PubMed    


  213. MADIAS JE
    Letter by Madias Regarding Article, "NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Deco
    Circulation. 2018;138:1908-1909.
    PubMed    


  214. MONTERO D
    Letter by Montero Regarding Article, "Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications for Heart Failure Prevention".
    Circulation. 2018;138:1757-1758.
    PubMed    


  215. CALVERLEY TA, Bailey DM
    Letter by Calverley and Bailey Regarding Article, "Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications for Heart Failure Prevention".
    Circulation. 2018;138:1755-1756.
    PubMed    


  216. HOWDEN EJ, Levine BD
    Response by Howden and Levine to Letters Regarding Article, "Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications for Heart Failure Prevention".
    Circulation. 2018;138:1759-1760.
    PubMed    


  217. ALOIA E
    Letter by Aloia Regarding Article, "Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality".
    Circulation. 2018;138:1612.
    PubMed    


  218. NUNEZ J, Nunez E, Sanchis J, Bayes-Genis A, et al
    Response by Nunez et al to Letter Regarding Article, "Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality".
    Circulation. 2018;138:1613-1614.
    PubMed    


    September 2018
  219. DAWSON J
    Pioglitazone Use After Stroke.
    Circulation. 2018;138:1221-1223.
    PubMed    


  220. COLOMBO PC, Mehra MR, Goldstein DJ, Estep JD, et al
    Comprehensive Analysis of Stroke in the LongTerm Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the HeartMate 3 Versus the HeartMate II Cardiac Pump.
    Circulation. 2018 Sep 17. doi: 10.1161/CIRCULATIONAHA.118.037231.
    PubMed     Abstract available


  221. GREENE SJ, Mentz RJ, Fiuzat M, Butler J, et al
    Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.
    Circulation. 2018;138:1039-1053.
    PubMed     Abstract available


    August 2018
  222. BERTERO E, Canepa M, Maack C, Ameri P, et al
    Linking Heart Failure to Cancer.
    Circulation. 2018;138:735-742.
    PubMed     Abstract available


  223. ALOIA E
    Letter by Aloia Regarding Article, "Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Su
    Circulation. 2018;138:656-657.
    PubMed    


  224. SOLIMAN O, Akin S, Muslem R, Caliskan K, et al
    Response by Soliman et al to Letter Regarding Article, "Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients With Mecha
    Circulation. 2018;138:658-659.
    PubMed    


  225. SARRIAS A, Bayes-Genis A
    Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
    Circulation. 2018;138:551-553.
    PubMed    


    July 2018
  226. BEALE AL, Meyer P, Marwick TH, Lam CSP, et al
    Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2018;138:198-205.
    PubMed     Abstract available


  227. ANAND IS, Gupta P
    Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies.
    Circulation. 2018;138:80-98.
    PubMed     Abstract available


  228. ROGER VL
    Heart Failure Epidemic: It's Complicated....
    Circulation. 2018;138:25-28.
    PubMed    


  229. SATTAR N, McGuire DK
    Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
    Circulation. 2018;138:7-9.
    PubMed    


    June 2018
  230. MCALLISTER DA, Read S, Kerssens J, Livingstone S, et al
    Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes.
    Circulation. 2018 Jun 27. pii: CIRCULATIONAHA.118.034986.
    PubMed     Abstract available


  231. YOUNG LH, Viscoli CM, Schwartz GG, Inzucchi SE, et al
    Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
    Circulation. 2018 Jun 22. pii: CIRCULATIONAHA.118.034763.
    PubMed     Abstract available



  232. Correction to: Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury.
    Circulation. 2018;137:e853.
    PubMed    


  233. SHARMA A, Hijazi Z, Andersson U, Al-Khatib SM, et al
    The Use of Biomarkers to Predict Specific Causes of Death in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.
    Circulation. 2018 Jun 5. pii: CIRCULATIONAHA.118.034125.
    PubMed     Abstract available


    May 2018
  234. PACKER M, Kowey PR
    Building Castles in the Sky: Catheter Ablation in Patients With Atrial Fibrillation and Chronic Heart Failure.
    Circulation. 2018 May 30. pii: CIRCULATIONAHA.118.034583.
    PubMed     Abstract available


  235. MEHRA MR, Salerno C, Cleveland JC, Pinney S, et al
    Health Care Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study: A Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure.
    Circulation. 2018 May 27. pii: CIRCULATIONAHA.118.035722.
    PubMed     Abstract available


  236. FUDIM M, Jones WS, Boortz-Marx RL, Ganesh A, et al
    Splanchnic Nerve Block for Acute Heart Failure.
    Circulation. 2018 May 25. pii: CIRCULATIONAHA.118.035260.
    PubMed     Abstract available


  237. REDDY YNV, Carter RE, Obokata M, Redfield MM, et al
    A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction.
    Circulation. 2018 May 23. pii: CIRCULATIONAHA.118.034646.
    PubMed     Abstract available


  238. WALKER MA, Tian R
    Raising NAD in Heart Failure: Time to Translate?
    Circulation. 2018;137:2274-2277.
    PubMed    


  239. ELMING MB, Signorovitch J, Kober L, Thune JJ, et al
    Response by Elming et al to Letter Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure".
    Circulation. 2018;137:2190.
    PubMed    


  240. ADABAG S, Wininger M, Singh SN
    Letter by Adabag et al Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure".
    Circulation. 2018;137:2188-2189.
    PubMed    


  241. JANUZZI JL JR, Richards AM
    Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study.
    Circulation. 2018;137:2101-2103.
    PubMed    


  242. LYTVYN Y, Bjornstad P, Udell JA, Lovshin JA, et al
    Response by Lytvyn et al to Letter Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials".
    Circulation. 2018;137:1984-1985.
    PubMed    


  243. GROCOTT HP
    Letter by Grocott Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials".
    Circulation. 2018;137:1983.
    PubMed    


  244. PACKER M
    Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1981-1982.
    PubMed    


  245. GAZMURI RJ, Karmazyn M
    Letter by Gazmuri and Karmazyn Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1979-1980.
    PubMed    


    April 2018
  246. LEOPOLD JA
    Pulmonary Venous Remodeling in Pulmonary Hypertension: The Veins Take Center Stage.
    Circulation. 2018;137:1811-1813.
    PubMed    


  247. CHIANG DY, Alsina KM, Corradini E, Fitzpatrick M, et al
    Rearrangement of the Protein Phosphatase 1 Interactome During Heart Failure Progression.
    Circulation. 2018 Apr 18. pii: CIRCULATIONAHA.118.034361.
    PubMed     Abstract available


  248. KAMIMURA D, Cain LR, Mentz RJ, White WB, et al
    Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study.
    Circulation. 2018 Apr 16. pii: CIRCULATIONAHA.117.031912.
    PubMed     Abstract available


  249. CHEN LY, Chung MK, Allen LA, Ezekowitz M, et al
    Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association.
    Circulation. 2018 Apr 16. pii: CIR.0000000000000568.
    PubMed     Abstract available


  250. VALIENTE-ALANDI I, Potter SJ, Salvador AM, Schafer AE, et al
    Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.
    Circulation. 2018 Apr 13. pii: CIRCULATIONAHA.118.034609.
    PubMed     Abstract available


  251. KONSTAM MA, Kiernan MS, Bernstein D, Bozkurt B, et al
    Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2018 Apr 12. pii: CIR.0000000000000560.
    PubMed     Abstract available


  252. PACKER M
    Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
    Circulation. 2018;137:1614-1631.
    PubMed     Abstract available


    March 2018
  253. KUSHNIR A, Santulli G, Reiken SR, Coromilas E, et al
    Ryanodine Receptor Calcium Leak in Circulating B-Lymphocytes as a Biomarker in Heart Failure.
    Circulation. 2018 Mar 28. pii: CIRCULATIONAHA.117.032703.
    PubMed     Abstract available


  254. SWEITZER NK, Airhart S
    New Therapeutic Target in Heart Failure: Achieving and Maintaining Normokalemia.
    Circulation. 2018;137:1331-1333.
    PubMed    


  255. ANDERSSON C, Lyass A, Lin H, Kober L, et al
    Association of Genetic Variation in Coronary Artery Disease-Related Loci With the Risk of Heart Failure With Preserved Versus Reduced Ejection Fraction.
    Circulation. 2018;137:1290-1292.
    PubMed    


  256. AUBDOOL AA, Argunhan F, Thakore P, Brain SD, et al
    Response by Aubdool et al to Letters Regarding Article, "A Novel alpha-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure".
    Circulation. 2018;137:1201-1202.
    PubMed    


  257. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "A Novel alpha-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure".
    Circulation. 2018;137:1200.
    PubMed    


  258. TSUDA K
    Letter by Tsuda Regarding Article, "A Novel alpha-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure".
    Circulation. 2018;137:1198-1199.
    PubMed    


  259. RADHOLM K, Figtree G, Perkovic V, Solomon SD, et al
    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Circulation. 2018 Mar 11. pii: CIRCULATIONAHA.118.034222.
    PubMed     Abstract available


  260. CHANG PP, Wruck LM, Shahar E, Rossi JS, et al
    Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): The Atherosclerosis Risk in Communities (ARIC) Study Community Surveillance.
    Circulation. 2018 Mar 8. pii: CIRCULATIONAHA.117.027551.
    PubMed     Abstract available


  261. VIJAYAKUMAR S, Vaduganathan M, Butler J
    Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.
    Circulation. 2018;137:1060-1073.
    PubMed     Abstract available


    February 2018
  262. MORINE KJ, Qiao X, York S, Natov PS, et al
    Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.
    Circulation. 2018 Feb 27. pii: CIRCULATIONAHA.117.031635.
    PubMed     Abstract available


  263. KOSIBOROD M, Cavender MA, Fu AZ, Wilding JP, et al
    Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of C
    Circulation. 2018;137:989-991.
    PubMed    


  264. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovas
    Circulation. 2018;137:988.
    PubMed    


  265. TAEGTMEYER H, Karlstaedt A
    Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Card
    Circulation. 2018;137:986-987.
    PubMed    


  266. KOH KK
    Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in
    Circulation. 2018;137:984-985.
    PubMed    


  267. TAMPAKI EC, Tampakis A, Pantos C
    Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular O
    Circulation. 2018;137:982-983.
    PubMed    


  268. PINA IL, Zheng Q, She L, Szwed H, et al
    Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).
    Circulation. 2018;137:771-780.
    PubMed     Abstract available


  269. WENGER NK
    Sauce for the Goose Versus Sauce for the Gander: Should Men and Women Play the Same Game But With Different Rules?
    Circulation. 2018;137:791-793.
    PubMed    


  270. ZHOU L, Miao K, Yin B, Li H, et al
    The Cardioprotective Role of Myeloid-derived Suppressor Cells in Heart Failure.
    Circulation. 2018 Feb 1. pii: CIRCULATIONAHA.117.030811.
    PubMed     Abstract available


    January 2018
  271. FLORIDO R, Kwak L, Lazo M, Nambi V, et al
    Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study.
    Circulation. 2018 Jan 31. pii: CIRCULATIONAHA.117.030226.
    PubMed     Abstract available


  272. REDDY YNV, Obokata M, Gersh BJ, Borlaug BA, et al
    High Prevalence of Occult Heart Failure With Preserved Ejection Fraction Among Patients With Atrial Fibrillation and Dyspnea.
    Circulation. 2018;137:534-535.
    PubMed    


  273. KUMBHANI DJ, Fonarow GC, Heidenreich PA, Schulte PJ, et al
    Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure.
    Circulation. 2018 Jan 29. pii: CIRCULATIONAHA.117.028077.
    PubMed     Abstract available


  274. OBOKATA M, Borlaug BA
    Response by Obokata and Borlaug to Letters Regarding Article, "Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2018;137:416-417.
    PubMed    


  275. CARBONE S, Canada JM, Abbate A
    Letter by Carbone et al Regarding Article, "Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2018;137:414-415.
    PubMed    


  276. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2018;137:413.
    PubMed    


  277. KOUTSAMPASOPOULOS K, Ouzouni C, Vogiatzis I
    Letter by Koutsampasopoulos et al Regarding Article, "Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2018;137:411-412.
    PubMed    


  278. PANDEY A, Omar W, Ayers C, LaMonte M, et al
    Sex and Race Differences in Lifetime Risk of Heart Failure with Preserved Ejection Fraction and Heart Failure with Reduced Ejection Fraction.
    Circulation. 2018 Jan 19. pii: CIRCULATIONAHA.117.031622.
    PubMed     Abstract available


  279. AHMAD T, Jackson K, Rao VS, Tang WHW, et al
    Worsening Renal Function in Acute Heart Failure Patients Undergoing Aggressive Diuresis is Not Associated with Tubular Injury.
    Circulation. 2018 Jan 19. pii: CIRCULATIONAHA.117.030112.
    PubMed     Abstract available


  280. AIMO A, Januzzi JL Jr, Vergaro G, Ripoli A, et al
    Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.
    Circulation. 2018;137:286-297.
    PubMed     Abstract available


  281. BORLAUG BA
    Can Oxygen Transport Analysis Tell Us Why People With Heart Failure With Preserved Ejection Fraction Feel So Poorly?
    Circulation. 2018;137:162-165.
    PubMed    


  282. JOLLY SS, Gao P, Cairns JA, Yusuf S, et al
    Risks of Overinterpreting Interim Data: Lessons From the TOTAL Trial (Thrombectomy With PCI Versus PCI Alone in Patients With STEMI).
    Circulation. 2018;137:206-209.
    PubMed    


  283. NAMBI V, Deswal A, Ballantyne CM
    Prevention of "Failure": Is It a Failure of Prevention?
    Circulation. 2018;137:106-108.
    PubMed    


  284. HOUSTIS NE, Eisman AS, Pappagianopoulos PP, Wooster L, et al
    Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O2 Pathway Analysis.
    Circulation. 2018;137:148-161.
    PubMed     Abstract available


  285. HOWDEN EJ, Sarma S, Lawley JS, Opondo M, et al
    Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications For Heart Failure Prevention.
    Circulation. 2018 Jan 8. pii: CIRCULATIONAHA.117.030617.
    PubMed     Abstract available


  286. GERSTEIN HC, Jung H, Ryden L, Diaz R, et al
    Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).
    Circulation. 2018;137:88-90.
    PubMed    


  287. STEHLIK J, Kobashigawa J, Hunt SA, Reichenspurner H, et al
    Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review.
    Circulation. 2018;137:71-87.
    PubMed     Abstract available


  288. CHUGH SS
    Disrupting the Approach to Sudden Cardiac Death: From Vulnerable Ejection Fraction to Vulnerable Patient.
    Circulation. 2018;137:7-9.
    PubMed    


    December 2017
  289. FAYYAZ AU, Edwards WD, Maleszewski JJ, Konik EA, et al
    Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated with Heart Failure and Preserved or Reduced Ejection Fraction.
    Circulation. 2017 Dec 15. pii: CIRCULATIONAHA.117.031608.
    PubMed     Abstract available


  290. STIENEN S, Salah K, Moons AH, Bakx AL, et al
    NT-proBNP-Guided Therapy in Acute Decompensated Heart Failure: The PRIMA II Randomized Controlled Trial.
    Circulation. 2017 Dec 14. pii: CIRCULATIONAHA.117.029882.
    PubMed     Abstract available


  291. WU S, Lu Q, Wang Q, Ding Y, et al
    Binding of FUN14 Domain Containing 1 With Inositol 1,4,5-Trisphosphate Receptor in Mitochondria-Associated Endoplasmic Reticulum Membranes Maintains Mitochondrial Dynamics and Function in Hearts in Vivo.
    Circulation. 2017;136:2248-2266.
    PubMed     Abstract available


    November 2017
  292. DU J, Ma XL, Li Y, Chen B, et al
    Response by Du et al to Letter Regarding Article, "Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling".
    Circulation. 2017;136:2094-2095.
    PubMed    


  293. LI Y, Liu B, Liang C
    Letter by Li et al Regarding Article, "Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling".
    Circulation. 2017;136:2092-2093.
    PubMed    


  294. FELDMAN T, Mauri L, Kahwash R, Litwin S, et al
    A Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial.
    Circulation. 2017 Nov 15. pii: CIRCULATIONAHA.117.032094.
    PubMed     Abstract available


  295. UDELL JA, Yuan Z, Rush T, Sicignano NM, et al
    Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study.
    Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.031227.
    PubMed     Abstract available



  296. Correction to: Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2017;136:e345.
    PubMed    


  297. MEHRA MR, Sundareswaran KS, Uriel N
    Response by Mehra et al to Letter Regarding Article, "Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure".
    Circulation. 2017;136:1872-1873.
    PubMed    


  298. MALTAIS S, Tchantchaleishvili V, Stulak JM
    Letter by Maltais et al Regarding Article, "Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure".
    Circulation. 2017;136:1870-1871.
    PubMed    


  299. AL-KHATIB SM, Pokorney SD
    Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: Diminishing Returns With Advancing Age?
    Circulation. 2017;136:1781-1783.
    PubMed    


    October 2017
  300. LYTVYN Y, Bjornstad P, Udell JA, Lovshin JA, et al
    Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Circulation. 2017;136:1643-1658.
    PubMed     Abstract available


  301. MANN DL
    High-Resolution Chromatin Mapping in Heart Failure: Some Answers, but More Questions.
    Circulation. 2017;136:1626-1628.
    PubMed    


  302. WOLSK E, Claggett B, Diaz R, Dickstein K, et al
    Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1560-1562.
    PubMed    


  303. PACKER M
    Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
    Circulation. 2017;136:1548-1559.
    PubMed     Abstract available


  304. RAU CD, Vondriska TM
    DNA Methylation and Human Heart Failure: Mechanisms or Prognostics.
    Circulation. 2017;136:1545-1547.
    PubMed    


  305. BUTLER J, Anker SD
    The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Circulation. 2017;136:1459-1461.
    PubMed    


  306. NUNEZ J, Bayes-Genis A, Zannad F, Rossignol P, et al
    Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality.
    Circulation. 2017 Oct 12. pii: CIRCULATIONAHA.117.030576.
    PubMed     Abstract available


  307. KATZ SD
    "Pumping Iron" to Improve Exercise Performance in Heart Failure: New Data and New Guidelines.
    Circulation. 2017;136:1384-1386.
    PubMed    


  308. CHO JH, Zhang R, Kilfoil PJ, Gallet R, et al
    Delayed Repolarization Underlies Ventricular Arrhythmias in Rats with Heart Failure and Preserved Ejection Fraction.
    Circulation. 2017 Oct 3. pii: CIRCULATIONAHA.117.028202.
    PubMed     Abstract available


    September 2017
  309. ROWIN EJ, Hausvater A, Link MS, Abt P, et al
    Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Circulation. 2017 Sep 15. pii: CIRCULATIONAHA.117.029267.
    PubMed     Abstract available


  310. PANDEY A, Berry JD
    Physical Activity in Heart Failure With Preserved Ejection Fraction: Moving Toward a Newer Treatment Paradigm.
    Circulation. 2017;136:993-995.
    PubMed    


  311. ELMING MB, Nielsen JC, Haarbo J, Videbaek L, et al
    Age and Outcomes of Primary Prevention Implantable Cardioverter Defibrillators in Patients with Non-Ischemic Systolic Heart Failure.
    Circulation. 2017 Sep 6. pii: CIRCULATIONAHA.117.028829.
    PubMed     Abstract available


  312. WAAGSTEIN F, Rutherford JD
    The Evolution of the Use of beta-Blockers to Treat Heart Failure: A Conversation With Finn Waagstein, MD.
    Circulation. 2017;136:889-893.
    PubMed     Abstract available


    August 2017
  313. CHRISTIANSEN MN, Kober L, Andersson C
    Response by Christiansen et al to Letters Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012".
    Circulation. 2017;136:886-887.
    PubMed    


  314. KAUL P, Ezekowitz JA, McAlister FA
    Letter by Kaul et al Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012".
    Circulation. 2017;136:884-885.
    PubMed    


  315. GABET A, Juilliere Y, Olie V
    Letter by Gabet et al Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012".
    Circulation. 2017;136:883.
    PubMed    


  316. SOLIMAN OI, Akin S, Muslem R, Boersma E, et al
    Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices:The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk
    Circulation. 2017 Aug 27. pii: CIRCULATIONAHA.117.030543.
    PubMed     Abstract available


  317. MEDER B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, et al
    Epigenome-Wide Association Study Identifies Cardiac Gene Patterning and A Novel Class of Biomarkers for Heart Failure.
    Circulation. 2017 Aug 24. pii: CIRCULATIONAHA.117.027355.
    PubMed     Abstract available


  318. CHANG LL, DeVore AD, Granger BB, Eapen ZJ, et al
    Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes.
    Circulation. 2017;136:765-772.
    PubMed     Abstract available


  319. ROSA-GARRIDO M, Chapski DJ, Schmitt AD, Kimball TH, et al
    High Resolution Mapping of Chromatin Conformation in Cardiac Myocytes Reveals Structural Remodeling of the Epigenome in Heart Failure.
    Circulation. 2017 Aug 11. pii: CIRCULATIONAHA.117.029430.
    PubMed     Abstract available


  320. ELLINGSEN O, Halle M, Prescott E, Linke A, et al
    Response by Ellingsen et al to Letters Regarding Article, "High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction".
    Circulation. 2017;136:611-612.
    PubMed    


  321. BIANCHI VE
    Letter by Bianchi Regarding Article, "High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction".
    Circulation. 2017;136:609-610.
    PubMed    


  322. WISLOFF U, Lavie CJ, Rognmo O
    Letter by Wisloff et al Regarding Article, "High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction".
    Circulation. 2017;136:607-608.
    PubMed    


  323. IELLAMO F, Volterrani M
    Letter by Iellamo and Volterrani Regarding Article, "High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction".
    Circulation. 2017;136:605-606.
    PubMed    


  324. KUEHN BM
    How Low Is Too Low With Salt in Heart Failure? Randomized Studies Needed to Resolve Concern.
    Circulation. 2017;136:597-598.
    PubMed    


  325. KALMAN JM, Sanders P, Rosso R, Calkins H, et al
    Should We Perform Catheter Ablation for Asymptomatic Atrial Fibrillation?
    Circulation. 2017;136:490-499.
    PubMed     Abstract available


    July 2017
  326. OBOKATA M, Borlaug BA
    Response by Obokata and Borlaug to Letter Regarding Article, "Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study".
    Circulation. 2017;136:430-431.
    PubMed    


  327. SMISETH OA, Nagueh SF
    Letter by Smiseth and Nagueh et al Regarding Article, "Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study".
    Circulation. 2017;136:428-429.
    PubMed    


  328. MCALISTER FA, Youngson E, Kaul P
    Health Resource Implications of Heart Failure Hospitalizations in Younger Patients Compared With Older Patients.
    Circulation. 2017;136:424-427.
    PubMed    


  329. KAPUR NK, Esposito ML, Bader Y, Morine KJ, et al
    Mechanical Circulatory Support Devices for Acute Right Ventricular Failure.
    Circulation. 2017;136:314-326.
    PubMed     Abstract available


  330. VAN VELDHUISEN DJ, Ponikowski P, van der Meer P, Metra M, et al
    Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency.
    Circulation. 2017 Jul 12. pii: CIRCULATIONAHA.117.027497.
    PubMed     Abstract available


  331. GILSTRAP LG, DeFilippis EM, Stevenson LW
    An Unintended Consequence of the 21st-Century Cures Act for Patients With Heart Failure.
    Circulation. 2017;136:123-125.
    PubMed    


  332. AHMAD FS, Chan C, Rosenman MB, Post WS, et al
    Validity of Cardiovascular Data From Electronic Sources:The Multi-Ethnic Study of Atherosclerosis and HealthLNK.
    Circulation. 2017 Jul 7. pii: CIRCULATIONAHA.117.027436.
    PubMed     Abstract available


  333. KITZMAN DW, Lam CSP
    Obese Heart Failure With Preserved Ejection Fraction Phenotype: From Pariah to Central Player.
    Circulation. 2017;136:20-23.
    PubMed    


    June 2017
  334. HEGDE S, Claggett B, Shah AM, Lewis EF, et al
    Physical Activity and Prognosis in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
    Circulation. 2017 Jun 21. pii: CIRCULATIONAHA.117.028002.
    PubMed     Abstract available


  335. RUBIN GA, Grinspan LT, Ginns J
    Of a Tortuous Nature: An Unusual Cause of Peripartum Congestive Heart Failure.
    Circulation. 2017;135:2567-2571.
    PubMed    


  336. TAJEU GS, Booth JN 3rd, Colantonio LD, Gottesman RF, et al
    Incident Cardiovascular Disease Among Adults with Blood Pressure < 140/90 mm Hg.
    Circulation. 2017 Jun 20. pii: CIRCULATIONAHA.117.027362.
    PubMed     Abstract available


    May 2017
  337. PARIKH KS, Lippmann SJ, Greiner M, Heidenreich PA, et al
    Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
    Circulation. 2017;135:2077-2080.
    PubMed    


  338. DAVIS J
    Putting the Brakes on Hypertensive Remodeling: An ATF3 Mechanism of Myofibroblast Restraint.
    Circulation. 2017;135:2058-2061.
    PubMed    


  339. KOSIBOROD M, Cavender MA, Fu AZ, Wilding JP, et al
    Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study.
    Circulation. 2017 May 18. pii: CIRCULATIONAHA.117.029190.
    PubMed     Abstract available


    April 2017
  340. YANCY CW, Jessup M, Bozkurt B, Butler J, et al
    2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of
    Circulation. 2017 Apr 28. pii: CIR.0000000000000509.
    PubMed    


  341. AUBDOOL AA, Thakore P, Argunhan F, Smillie SJ, et al
    A Novel alpha-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy and Heart Failure.
    Circulation. 2017 Apr 26. pii: CIRCULATIONAHA.117.028388.
    PubMed     Abstract available


  342. CHOW SL, Maisel AS, Anand I, Bozkurt B, et al
    Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2017 Apr 26. pii: CIR.0000000000000490.
    PubMed     Abstract available


  343. BRESS AP, Kramer H, Khatib R, Beddhu S, et al
    Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examina
    Circulation. 2017;135:1617-1628.
    PubMed     Abstract available


  344. VERMA A, Kalman JM, Callans DJ
    Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction.
    Circulation. 2017;135:1547-1563.
    PubMed     Abstract available


  345. GORTER TM, Rienstra M, van Veldhuisen DJ
    Measuring Pulmonary Artery Pressures in Heart Failure: A New Useful Diagnostic Tool?
    Circulation. 2017;135:1518-1521.
    PubMed    


  346. GORI M, Senni M, Metra M
    High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure: Are We Ready for Prime Time?
    Circulation. 2017;135:1506-1508.
    PubMed    


  347. PACKER M
    Response by Packer to Letter Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective".
    Circulation. 2017;135:e892-e893.
    PubMed    


  348. BROWN PM, Ezekowitz JA
    Letter by Brown and Ezekowitz Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective".
    Circulation. 2017;135:e889-e891.
    PubMed    


  349. URIEL N, Colombo PC, Cleveland JC, Long JW, et al
    Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
    Circulation. 2017 Apr 6. pii: CIRCULATIONAHA.117.028303.
    PubMed     Abstract available


  350. OBOKATA M, Reddy YN, Pislaru SV, Melenovsky V, et al
    Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction.
    Circulation. 2017 Apr 5. pii: CIRCULATIONAHA.116.026807.
    PubMed     Abstract available


  351. LAM CS, Solomon SD
    Fussing Over the Middle Child: Heart Failure With Mid-Range Ejection Fraction.
    Circulation. 2017;135:1279-1280.
    PubMed    


    March 2017
  352. ROSAMOND WD, Johnson A
    Trends in Heart Failure Incidence in the Community: A Gathering Storm.
    Circulation. 2017;135:1224-1226.
    PubMed    


  353. METHAWASIN M, Granzier H
    Response by Methawasin and Granzier to Letter Regarding Article, "Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure With Preserved Ejection F
    Circulation. 2017;135:e681-e682.
    PubMed    


  354. LEWIS GA, Miller CA
    Letter by Lewis and Miller Regarding Article, "Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure With Preserved Ejection Fraction".
    Circulation. 2017;135:e679-e680.
    PubMed    


  355. SISCOVICK DS, Barringer TA, Fretts AM, Wu JH, et al
    Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.
    Circulation. 2017 Mar 13. pii: CIR.0000000000000482.
    PubMed     Abstract available


  356. FIDLER MM, Reulen RC, Henson K, Kelly J, et al
    Population-Based Long-Term Cardiac-Specific Mortality Among 34 489 Five-Year Survivors of Childhood Cancer in Great Britain.
    Circulation. 2017;135:951-963.
    PubMed     Abstract available


  357. SUNDSTROM J, Bruze G, Ottosson J, Marcus C, et al
    Weight Loss and Heart Failure: A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment.
    Circulation. 2017 Mar 3. pii: CIRCULATIONAHA.116.025629.
    PubMed     Abstract available


  358. LI Y, Li Z, Zhang C, Li P, et al
    Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.
    Circulation. 2017 Mar 1. pii: CIRCULATIONAHA.116.024599.
    PubMed     Abstract available


    February 2017
  359. KONSTAM MA, Abboud FM
    Ejection Fraction: Misunderstood and Overrated (Changing the Paradigm in Categorizing Heart Failure).
    Circulation. 2017;135:717-719.
    PubMed    


  360. CHRISTIANSEN MN, Kober L, Weeke P, Vasan RS, et al
    Age-specific Trends in Incidence, Mortality and Comorbidities of Heart Failure in Denmark 1995-2012.
    Circulation. 2017 Feb 7. pii: CIRCULATIONAHA.116.025941.
    PubMed     Abstract available


  361. TIBURCY M, Hudson JE, Balfanz P, Schlick SF, et al
    Defined Engineered Human Myocardium with Advanced Maturation for Applications in Heart Failure Modelling and Repair.
    Circulation. 2017 Feb 6. pii: CIRCULATIONAHA.116.024145.
    PubMed     Abstract available


  362. SELIGER SL, Hong SN, Christenson RH, Kronmal R, et al
    High Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: The Multi-Ethnic Study of Atherosclerosis.
    Circulation. 2017 Feb 3. pii: CIRCULATIONAHA.116.025505.
    PubMed     Abstract available


  363. RAO MP, Al-Khatib SM, Pokorney S, She L, et al
    Sudden Cardiac Death in Patients with Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results from the Surgical Treatment for Ischemic Heart Failure (STICH) Randomized Clinical Trial.
    Circulation. 2017 Feb 2. pii: CIRCULATIONAHA.116.026075.
    PubMed     Abstract available


    January 2017
  364. SAIKI H, Petersen IA, Scott CG, Bailey KR, et al
    Risk of Heart Failure with Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer.
    Circulation. 2017 Jan 29. pii: CIRCULATIONAHA.116.025434.
    PubMed     Abstract available


  365. PENG D, Zhang Y, Rosenthal DN, Palmon M, et al
    Impact of Heart Transplantation on the Functional Status of U.S. Children with End-Stage Heart Failure. Analysis of Data from the Organ Procurement and Transplantation Network.
    Circulation. 2017 Jan 24. pii: CIRCULATIONAHA.115.016520.
    PubMed     Abstract available


  366. ATZLER D, McAndrew DJ, Cordts K, Schneider JE, et al
    Dietary Supplementation with Homoarginine Preserves Cardiac Function in a Murine Model of Post-Myocardial Infarction Heart Failure.
    Circulation. 2017;135:400-402.
    PubMed    


  367. NARAYAN HK, Finkelman BS, French B, Plappert T, et al
    Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations with Ejection Fraction Decline, Recovery, and Heart Failure Symptoms over 3 Years of Followup.
    Circulation. 2017 Jan 19. pii: CIRCULATIONAHA.116.023463.
    PubMed     Abstract available


  368. HESS PL, Hernandez AF, Bhatt DL, Hellkamp AS, et al
    Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failur
    Circulation. 2017;135:e22-e23.
    PubMed    


  369. DHRUVA SS, Redberg RF
    Letter by Dhruva and Redberg Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Pr
    Circulation. 2017;135:e20-e21.
    PubMed    


  370. ELLINGSEN O, Halle M, Conraads VM, Stoylen A, et al
    High Intensity Interval Training in Heart Failure Patients with Reduced Ejection Fraction.
    Circulation. 2017 Jan 12. pii: CIRCULATIONAHA.116.022924.
    PubMed     Abstract available


  371. SEIDEL T, Navankasattusas S, Ahmad AA, Diakos NA, et al
    Sheet-Like Remodeling of the Transverse Tubular System in Human Heart Failure Impairs Excitation-Contraction Coupling and Functional Recovery by Mechanical Unloading.
    Circulation. 2017 Jan 10. pii: CIRCULATIONAHA.116.024470.
    PubMed     Abstract available


  372. KRISTENSEN SL, Mogensen UM, Jhund PS, Petrie MC, et al
    Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction. A Report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Tria
    Circulation. 2017 Jan 4. pii: CIRCULATIONAHA.116.024593.
    PubMed     Abstract available


    December 2016
  373. OBOKATA M, Kane GC, Reddy YN, Olson TP, et al
    The Role of Diastolic Stress Testing in the Evaluation for HFpEF:A Simultaneous Invasive-Echocardiographic Study.
    Circulation. 2016 Dec 30. pii: CIRCULATIONAHA.116.024822.
    PubMed     Abstract available


  374. JOLLY SS, James SK, Dzavik V, Cairns JA, et al
    Thrombus Aspiration in ST Elevation Myocardial Infarction: An Individual Patient Meta-analysis.
    Circulation. 2016 Dec 9. pii: CIRCULATIONAHA.116.025371.
    PubMed     Abstract available


  375. MARQUES FZ, Nelson EM, Chu PY, Horlock D, et al
    High Fibre Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in DOCA-Salt Hypertensive Mice.
    Circulation. 2016 Dec 7. pii: CIRCULATIONAHA.116.024545.
    PubMed     Abstract available


  376. ABU-TAHA IH, Heijman J, Hippe HJ, Wolf NM, et al
    Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in Human Heart Failure.
    Circulation. 2016 Dec 7. pii: CIRCULATIONAHA.116.022852.
    PubMed     Abstract available


    November 2016
  377. NADRUZ W JR, Claggett BL, McMurray JJ, Packer M, et al
    Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Pros
    Circulation. 2016;134:1785-1787.
    PubMed    


  378. SHAH AM, Claggett B, Loehr LR, Chang PP, et al
    Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
    Circulation. 2016 Nov 23. pii: CIRCULATIONAHA.116.023361.
    PubMed     Abstract available


  379. MCEVOY JW, Martin SS, Dardari ZA, Miedema MD, et al
    Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy.
    Circulation. 2016 Nov 23. pii: CIRCULATIONAHA.116.025471.
    PubMed     Abstract available


  380. PACKER M
    Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective.
    Circulation. 2016;134:1664-1678.
    PubMed     Abstract available


  381. GAGGIN HK, Liu Y, Lyass A, van Kimmenade RR, et al
    Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography.
    Circulation. 2016 Nov 21. pii: CIRCULATIONAHA.116.023052.
    PubMed     Abstract available


  382. MEHRA MR, Lindenfeld J
    Highlights of the Annual Scientific Meeting of the Heart Failure Society of America 2016.
    Circulation. 2016;134:1505-1506.
    PubMed    


  383. ZUHLKE L, Karthikeyan G, Engel ME, Rangarajan S, et al
    Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study).
    Circulation. 2016;134:1456-1466.
    PubMed     Abstract available


  384. LYNGBAKKEN MN, Skranes JB, de Lemos JA, Nygard S, et al
    Impact of Smoking on Circulating Cardiac Troponin I Concentrations and Cardiovascular Events in the General Population: The HUNT Study.
    Circulation. 2016 Nov 4. pii: CIRCULATIONAHA.116.023726.
    PubMed     Abstract available


  385. WANG Q, Liu Y, Fu Q, Xu B, et al
    Inhibiting Insulin-Mediated beta2AR Activation Prevents Diabetes-Associated Cardiac Dysfunction.
    Circulation. 2016 Nov 4. pii: CIRCULATIONAHA.116.022281.
    PubMed     Abstract available


  386. MCKELLAR SH, Fang JC
    An Age-Old Question: What Is Too Old for Coronary Artery Bypass Grafting in Heart Failure?
    Circulation. 2016;134:1325-1327.
    PubMed    


  387. AL-KHATIB SM, Friedman P, Ellenbogen KA
    Defibrillators: Selecting the Right Device for the Right Patient.
    Circulation. 2016;134:1390-1404.
    PubMed     Abstract available


    October 2016
  388. BOZKURT B, Aguilar D, Deswal A, Dunbar SB, et al
    Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2016 Oct 31. pii: CIR.0000000000000450.
    PubMed    


  389. FILIPPOV AA, Del Nido PJ, Vasilyev NV
    Management of Systemic Right Ventricular Failure in Patients With Congenitally Corrected Transposition of the Great Arteries.
    Circulation. 2016;134:1293-1302.
    PubMed     Abstract available


  390. FRIEDMAN DJ, Bao H, Spatz ES, Curtis JP, et al
    Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: A Report from the National Cardiovascular Data Registry.
    Circulation. 2016 Oct 19. pii: CIRCULATIONAHA.116.022913.
    PubMed     Abstract available


  391. LEWINTER MM, Zile MR
    Could Modification of Titin Contribute to an Answer for Heart Failure With Preserved Ejection Fraction?
    Circulation. 2016;134:1100-1104.
    PubMed    


  392. METHAWASIN M, Strom JG, Slater RE, Fernandez V, et al
    Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2016;134:1085-1099.
    PubMed     Abstract available



  393. Correction to: Heart Failure With Preserved Ejection Fraction: A Kidney Disorder?
    Circulation. 2016;134:e307.
    PubMed    


  394. COWIE MR
    Returning to Work: A Forgotten Aspect of Rehabilitation for Heart Failure.
    Circulation. 2016;134:1010-1012.
    PubMed    


    September 2016

  395. Correction to: 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart As
    Circulation. 2016;134:e298.
    PubMed    


  396. MELGARI D, Ng GA, Hancox JC
    Letter by Melgari et al Regarding Article, "Ivabradine: Role in the Chronic Heart Failure Armamentarium".
    Circulation. 2016;134:e296-7.
    PubMed    


  397. CALVERT PA, Northridge DB, Malik IS, Shapiro L, et al
    Percutaneous Device Closure of Paravalvular Leak: Combined Experience From the United Kingdom and Ireland.
    Circulation. 2016;134:934-44.
    PubMed     Abstract available



  398. Correction to: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2016;134:e261.
    PubMed    


  399. WIJESURENDRA RS, Liu A, Eichhorn C, Ariga R, et al
    "Lone" Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persist Despite Successful Catheter Ablation.
    Circulation. 2016 Sep 14. pii: CIRCULATIONAHA.116.022931.
    PubMed     Abstract available


    August 2016
  400. PACKER M
    Heart Failure's Dark Secret: Does Anyone Really Care About Optimal Medical Therapy?
    Circulation. 2016;134:629-31.
    PubMed    


    July 2016
  401. TAEGTMEYER H
    Failing Heart and Starving Brain: Ketone Bodies to the Rescue.
    Circulation. 2016;134:265-6.
    PubMed    


  402. RAJAPAKSE NW, Kuruppu S, Ian Smith A
    Letter by Rajapakse et al Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition".
    Circulation. 2016;134:e9-e10.
    PubMed    


  403. HUBERS SA, Brown NJ
    Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition".
    Circulation. 2016;134:e11-2.
    PubMed    


  404. HE VY, Condon JR, Ralph AP, Zhao Y, et al
    Long-Term Outcomes From Acute Rheumatic Fever and Rheumatic Heart Disease: A Data-Linkage and Survival Analysis Approach.
    Circulation. 2016;134:222-32.
    PubMed     Abstract available


    May 2016
  405. MCMURRAY JJ
    Disease Management Programs in Cardiology: Extending the Success in Failure.
    Circulation. 2016;133:1836-7.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: